Helixgate

Helixgate

Uncategorized

Eisai, Alzheon Drill Down on Promising Results in High-Risk Alzheimer’s Subset

Published

on

At the AD/PD annual meeting, Eisai presented real-world data suggesting Leqembi’s long-term safety and efficacy in people homozygous for APOE4, who were identified in trials as being at higher risk of brain bleeds while on the treatment. Alzheon, meanwhile, added further detail to trial results of its candidate in patients with the same genetic profile.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Terns rebuffed a higher bid before selling to Merck

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for rights to the coveted leukemia drug developer. 

Read More

Published

on

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for rights to the coveted leukemia drug developer. 

Read More

Continue Reading

Uncategorized

STAT+: States looking to regulate use of chatbots

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company. 

Continue to STAT+ to read the full story…

Read More

Published

on

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company. 

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

ARPA-H selects three teams in $100M effort to repair and regrow ailing joints

Published

on

Three academic centers believe they may have discovered new ways to heal aging joints. Now the federal government is funding clinical trials to test these experimental regenerative medicines in osteoarthritis.
Teams from Duke University, the …

Continue Reading
Advertisement

Trending